AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28103159 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sports training (instruction and practice)
Number of subjects: 73
Study 28103159 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (methylphenidate)
Number of subjects: 73
Study 28103159 — intervention group
Group type: COMPARATOR
Intervention: Medication (placebo)
Number of subjects: 73
Study 28103159 — intervention group
Group type: COMPARATOR
Intervention: Recreational play
Number of subjects: 73
Study 28103159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports training (instruction and practice)
Number of subjects: 73
Study 28103159 — intervention group
Group type: COMPARATOR
Intervention: Medication (methylphenidate) without sports training
Number of subjects: 73
Study 27842938 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and stretching training program (n = 84)
Number of subjects: 130
Study 27842938 — intervention group
Group type: COMPARATOR
Intervention: Control group attending PE classes (n = 46)
Number of subjects: 130
Study 25891307 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual reminiscence therapy (1 hour/week for 4 weeks)
Number of subjects: 78
Study 25891307 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 78
Study 24063204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongguan Capsule (TC)
Number of subjects: 60
Study 24063204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18165667 — intervention group
Group type: EXPERIMENTAL
Intervention: CTPA
Number of subjects: 1417
Study 18165667 — intervention group
Group type: COMPARATOR
Intervention: V(dot)Q(dot) scanning
Number of subjects: 1417
Study 14764772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline treatment for 6 months
Number of subjects: 51
Study 10800794 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI pacing at 10 beats/min or more above the resting heart rate (Paced)
Number of subjects: 100
Study 10800794 — intervention group
Group type: COMPARATOR
Intervention: No atrial pacing (Control)
Number of subjects: 100
Study 10800794 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI pacing (Paced)
Number of subjects: 100
Study 8620275 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MP) 1,000 mg every eight hours
Number of subjects: 129
Study 8620275 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 5 mg/kg/day and Clindamycin 900 mg every eight hours (T/C)
Number of subjects: 129
Study 8620275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MP and T/C)
Number of subjects: 129
Study 1428210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bjork‐Shiley (BS) prosthesis
Number of subjects: 150
Study 1428210 — intervention group
Group type: EXPERIMENTAL
Intervention: Starr‐Edwards (SE) prosthesis
Number of subjects: 150
Study 1428210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lillehei‐Kaste (LK) prosthesis
Number of subjects: 150
Study 1428210 — intervention group
Group type: COMPARATOR
Intervention: All prostheses (BS, LK, SE)
Number of subjects: 150
Study 4008075 — intervention group
Group type: EXPERIMENTAL
Intervention: monomethoxy polyethylene glycol‐coupled HBV (PEG‐HBV)
Number of subjects: 24
Study 4008075 — intervention group
Group type: COMPARATOR
Intervention: honey bee venom (HBV)
Number of subjects: 24
Study 29165000 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Better Caregivers (BBC) intervention
Number of subjects: 83
Study 25863600 — intervention group
Group type: EXPERIMENTAL
Intervention: Defusion
Number of subjects: 73
Study 25863600 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 73
Study 25863600 — intervention group
Group type: COMPARATOR
Intervention: Suppression
Number of subjects: 73
Study 23438314 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS followed by face-to-face (FF) coaching sessions
Number of subjects: 49
Study 23438314 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS followed by web-based (WEB) coaching sessions
Number of subjects: 49
Study 23438314 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (PBO) group
Number of subjects: 49
Study 20946286 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard electrocardiography (ECG) at first evaluation and follow-up
Number of subjects: 70
Study 20946286 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, presence of paroxysmal atrial flutter or fibrillation, number of CTG repeats
Number of subjects: 70
Study 20946286 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 70
Study 20946286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower left ventricular ejection fraction
Number of subjects: 70
Study 19793390 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus Depression Care for People with Lung Cancer
Number of subjects: 200
Study 19793390 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 18200773 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release nifedipine added once daily to ARB
Number of subjects: 0
Study 18200773 — intervention group
Group type: COMPARATOR
Intervention: Increasing ARB dosage
Number of subjects: 0
Study 15210257 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of personal health records (PHRs) by case managers (CMs) in one half of the patients.
Number of subjects: 150
Study 15210257 — intervention group
Group type: COMPARATOR
Intervention: Cohort without personal health records (PHRs).
Number of subjects: 150
Study 11190754 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 280 micrograms once daily
Number of subjects: 157
Study 11190754 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 140 micrograms once daily
Number of subjects: 157
Study 11190754 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 157
Study 11190754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 9355432 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% ointment
Number of subjects: 8
Study 8408738 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg)
Number of subjects: 13
Study 8408738 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 13
Study 3534900 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (single-dose)
Number of subjects: 12
Study 3534900 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (two-week trial)
Number of subjects: 12
Study 29856286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (5 to 7 sessions over 8 weeks)
Number of subjects: 0
Study 29856286 — intervention group
Group type: COMPARATOR
Intervention: Conventional psychiatric treatment (control group)
Number of subjects: 0
Study 27327616 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of MVA (MM group)
Number of subjects: 120
Study 27327616 — intervention group
Group type: COMPARATOR
Intervention: One injection of Placebo and one injection of MVA (PM group)
Number of subjects: 120
Study 25842580 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index monitoring
Number of subjects: 50
Study 25842580 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation with Ramsay score 5-6 without Bispectral Index monitoring
Number of subjects: 50
Study 22691240 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone reminders
Number of subjects: 6903
Study 22691240 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement strategies requiring a second dispensing event
Number of subjects: 6903
Study 22691240 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement strategies that do not require a dispensing event
Number of subjects: 6903
Study 20385666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide adsorber included in the CPB circuit
Number of subjects: 17
Study 20385666 — intervention group
Group type: COMPARATOR
Intervention: Control group (without adsorber)
Number of subjects: 17
Study 18926073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation guided by respiratory physiology, thrice a day, 15 minutes each time for 8 weeks.
Number of subjects: 60
Study 18926073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation with pursed lip respiration, thrice a day, 15 minutes each time for 8 weeks.
Number of subjects: 60
Study 18926073 — intervention group
Group type: COMPARATOR
Intervention: No pulmonary rehabilitation.
Number of subjects: 60
Study 16526176 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital
Number of subjects: 238
Study 16526176 — intervention group
Group type: COMPARATOR
Intervention: Inpatient ward
Number of subjects: 238
Study 16526176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both settings
Number of subjects: 238
Study 12714433 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (biochanin or formononetin, 80 mg/d)
Number of subjects: 80
Study 12714433 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (formononetin)
Number of subjects: 80
Study 12714433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10479203 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity in men
Number of subjects: 210
Study 10479203 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity in women
Number of subjects: 210
Study 10479203 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal status
Number of subjects: 210
Study 10479203 — intervention group
Group type: COMPARATOR
Intervention: Estrogen use
Number of subjects: 210
Study 8743188 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate 30 min cycle ergometer exercise
Number of subjects: 15
Study 8743188 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐term maximal exercise
Number of subjects: 15
Study 8743188 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 15
Study 8743188 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic exercise
Number of subjects: 15
Study 8743188 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 15
Study 8743188 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 15
Study 1713709 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-329 (10 mg orally)
Number of subjects: 6
Study 1713709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6351619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tinidazole, 500 mg twice daily for 5 days
Number of subjects: 30
Study 6351619 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo with vaginal cream (with or without sulfonamides)
Number of subjects: 30
Study 6351619 — intervention group
Group type: COMPARATOR
Intervention: Vaginal sulfonamide cream with oral placebo
Number of subjects: 30
Study 29025878 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor antagonist exendin 9-39 (Ex9-39)
Number of subjects: 10
Study 29025878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26542498 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated system of personalized educational reminders sent to patients and family physicians, mailed at 1, 2, 5, 8, and 11 months after discharge.
Number of subjects: 852
Study 26542498 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated system of personalized educational reminders
Number of subjects: 852
Study 26542498 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 852
Study 25951693 — intervention group
Group type: EXPERIMENTAL
Intervention: High school physiology education
Number of subjects: 1083
Study 25951693 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1083
Study 25951693 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-year students studying physiology
Number of subjects: 1083
Study 25951693 — intervention group
Group type: EXPERIMENTAL
Intervention: General knowledge of physiology
Number of subjects: 1083
Study 22622049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of MCV4
Number of subjects: 324
Study 22622049 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of MCV4
Number of subjects: 324
Study 22622049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of MCV4 in subjects with CD4% <15
Number of subjects: 324
Study 19417618 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral rifampin once daily for 7 days
Number of subjects: 12
Study 17332210 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual group (home asthma telemonitoring with store-and-forward technology)
Number of subjects: 120
Study 17332210 — intervention group
Group type: COMPARATOR
Intervention: Both groups (office-based and virtual)
Number of subjects: 120
Study 15382436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovesical treatment with Bacillus Calmette Guerin (BCG) for 12 months
Number of subjects: 90
Study 15382436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovesical treatment with Bacillus Calmette Guerin (BCG) for 6 months
Number of subjects: 90
Study 15382436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BCG treatment)
Number of subjects: 90
Study 11590992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 85
Study 9881512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 16
Study 9881512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 16
Study 9881512 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 7921059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0
Study 7921059 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 0
Study 7921059 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 0
Study 3293891 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-meat protein supplement
Number of subjects: 64
Study 3293891 — intervention group
Group type: COMPARATOR
Intervention: Meat protein supplement
Number of subjects: 64
Study 30318944 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium exposure
Number of subjects: 1747
Study 30318944 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic exposure
Number of subjects: 1747
Study 30318944 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing gestational age (GA) at delivery
Number of subjects: 1747
Study 30318944 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants that did not develop CP)
Number of subjects: 1747
Study 30392115 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day; 3 weeks on/1 week off) plus fulvestrant (500 mg)
Number of subjects: 35
Study 30392115 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (500 mg)
Number of subjects: 35
Study 28537501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR)
Number of subjects: 990
Study 28537501 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone controlled release (CR)
Number of subjects: 990
Study 28537501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study 28537501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Number of subjects: 990
Study 25856791 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 155
Study 25856791 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 155
Study 23046099 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite inhalation
Number of subjects: 18
Study 23046099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22031874 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (anodal over left DLPFC, cathodal over right supraorbital region)
Number of subjects: 13
Study 22031874 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study 19463380 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin resistant patients (ARU >= 550)
Number of subjects: 209
Study 19463380 — intervention group
Group type: COMPARATOR
Intervention: Aspirin sensitive patients
Number of subjects: 209
Study 19463380 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel low-responders (platelet inhibition <19%)
Number of subjects: 209
Study 19463380 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel responders
Number of subjects: 209
Study 16556246 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment for headaches
Number of subjects: 176
Study 14606081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 225
Study 14606081 — intervention group
Group type: COMPARATOR
Intervention: Serology
Number of subjects: 225
Study 11349487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft lip patients (n=20)
Number of subjects: 42
Study 11349487 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 healthy subjects)
Number of subjects: 42
Study 8792789 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlier practitioners identified based on performance evaluation.
Number of subjects: 430
Study 8792789 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance evaluation across cases seen by a given physician.
Number of subjects: 430
Study 8792789 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance correlation between guidelines.
Number of subjects: 430
Study 1363631 — intervention group
Group type: EXPERIMENTAL
Intervention: MAST‐CLA
Number of subjects: 195
Study 6476868 — intervention group
Group type: EXPERIMENTAL
Intervention: banked breast milk
Number of subjects: 194
Study 6476868 — intervention group
Group type: EXPERIMENTAL
Intervention: preterm formula
Number of subjects: 194
Study 6476868 — intervention group
Group type: COMPARATOR
Intervention: maternal milk supplemented with banked breast milk
Number of subjects: 194
Study 3537092 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 18
Study 3537092 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 18
Study 3537092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Albuterol
Number of subjects: 18
Study 30241150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2
Number of subjects: 70
Study 30241150 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin 15 IU/m2 and Vincristine 1.4 mg/m2
Number of subjects: 70
Study 30241150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Gemcitabine and BV
Number of subjects: 70
Study 26818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hummus alone (2.7 g, 10.8 g, 25 g avCHO)
Number of subjects: 10
Study 26818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hummus plus white bread (2.7 g, 5.4 g, 10.8 g avCHO)
Number of subjects: 10
Study 26818604 — intervention group
Group type: COMPARATOR
Intervention: White bread (25 g avCHO)
Number of subjects: 10
Study 26818604 — intervention group
Group type: COMPARATOR
Intervention: White bread (50 g avCHO)
Number of subjects: 10
Study 24745810 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (maintaining hemoglobin 10.0 g/dL > hemoglobin ≧ 8.0 g/dL)
Number of subjects: 186
Study 24745810 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (maintaining hemoglobin ≧ 10.0 g/dL)
Number of subjects: 186
Study 24745810 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 186
Study 24745810 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 186
Study 23479138 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (n = 9)
Number of subjects: 20
Study 23479138 — intervention group
Group type: COMPARATOR
Intervention: In-person care (n = 11)
Number of subjects: 20
Study 20855178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonarticulated pneumatic postamputation mobility aid (PPAMA)
Number of subjects: 29
Study 20855178 — intervention group
Group type: COMPARATOR
Intervention: Articulated amputee mobility aid (AMA)
Number of subjects: 29
Study 19265756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sony PlayStation II EyeToy
Number of subjects: 56
Study 16842396 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study 16842396 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin and warfarin or digoxin
Number of subjects: 0
Study 12491520 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptides/IFA with GM-CSF (250 microm subcutaneously daily for 5 days)
Number of subjects: 48
Study 12491520 — intervention group
Group type: COMPARATOR
Intervention: Peptides/IFA alone
Number of subjects: 48
Study 12491520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 10850937 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at doses of 0.075 IU/kg, 0.150 IU/kg, and 0.300 IU/kg for 5 postoperative days
Number of subjects: 104
Study 10850937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 8673754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily
Number of subjects: 25
Study 8673754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1818790 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (41 +/- 3 mg in three divided doses)
Number of subjects: 33
Study 1818790 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (8 +/- 1 mg once daily)
Number of subjects: 33
Study 6822483 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified patients treated with maprotiline (16 of 25)
Number of subjects: 1086
Study 6822483 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified patients electively not treated
Number of subjects: 1086
Study 6822483 — intervention group
Group type: COMPARATOR
Intervention: Control group (not identified)
Number of subjects: 1086
Study 31472076 — intervention group
Group type: EXPERIMENTAL
Intervention: Drought treatment
Number of subjects: 300
Study 31472076 — intervention group
Group type: COMPARATOR
Intervention: Non-droughted seedlings
Number of subjects: 300
Study 29526386 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic alphanumeric‐coded endoscopy
Number of subjects: 50